Loading...
01/11 16:18
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The partnership with Global Government Services is a strong positive, offering access to federal healthcare systems. Financial performance shows improvement, with increased revenue and reduced expenses. The Q&A reveals positive sentiment towards the adoption and geographic expansion of PoNS therapy. However, reimbursement challenges and financial constraints pose risks. Despite these, the optimistic guidance and strategic partnerships suggest a positive stock price movement, likely in the 2% to 8% range over the next two weeks.
Total Revenue $135,000 (up $24,000 or 21.6% year-over-year) due to increased product sales in both the U.S. and Canada.
Cost of Revenue $123,000 (up $1,000 or 0.8% year-over-year) remaining relatively flat due to fixed overhead costs.
Selling, General and Administrative Expenses $2.6 million (down $0.3 million or 10.3% year-over-year) due primarily to a decrease in professional fees and payroll-related expenses, partially offset by an increase in contract manufacturer expense.
Research and Development Expense $0.8 million (down $0.1 million or 11.1% year-over-year) driven primarily by a decrease in product development expenses and clinical trial activities.
Operating Loss $3.4 million (improved from a loss of $3.8 million year-over-year) indicating a reduction in losses.
Net Loss $2.5 million (unchanged year-over-year) with a loss of $3.08 per share compared to a loss of $4.42 per share in the prior year.
Cash Burn from Operations $3 million (down $0.2 million or 6.3% year-over-year) indicating improved cash management.
Cash Position $3.6 million in cash as of March 30, 2024, with no debt.
Public Offering Proceeds $6.4 million raised, with net proceeds of approximately $5.6 million, extending cash runway into 2025.
PoNS Device Pricing: The list price for the PoNS device in North America is $25,700, comprised of $17,800 for the controller and $7,900 for the mouthpiece.
PoNS Therapy for Stroke: Helius is pursuing FDA approval for PoNS therapy for stroke, with a target regulatory submission by early 2025.
Medicare Reimbursement: CMS established HCPCS codes for the PoNS mouthpiece and controller effective April 1, 2024, allowing Helius to negotiate reimbursement with third-party payers.
VA Partnership: Helius is now an approved supplier to the VA and DoD, making PoNS available to federal healthcare systems.
Canadian Market Expansion: In Canada, Helius is establishing sites in five regions as part of a government-funded initiative to validate PoNS therapy for stroke.
Financing: Helius announced a $6.4 million financing to extend its cash runway into 2025.
Cost Management: Selling, general and administrative expenses decreased to $2.6 million in Q1 2024 from $2.9 million in Q1 2023.
Regulatory Strategy: Helius aligned with the FDA to streamline the size, timeline, and cost of the stroke registrational program.
Reimbursement Risks: The preliminary Medicare payment determinations for the PoNS controller and mouthpiece are subject to change, which poses a risk to securing higher reimbursement rates. The company is advocating for higher rates based on their list price and the unique nature of their product.
Regulatory Approval Risks: The timeline for FDA approval for stroke is uncertain, with the company targeting regulatory submission by early 2025. Any delays or complications in this process could impact market access and revenue generation.
Market Adoption Risks: Despite the potential for increased revenues, PoNS sales currently remain on a cash-pay basis, which limits accessibility for many patients. The company needs to secure widespread reimbursement to boost sales.
Supply Chain Challenges: Transitioning to a new contract manufacturer has led to increased expenses, which could affect the company's cost structure and operational efficiency.
Financial Risks: The company reported a net loss of $2.5 million for Q1 2024 and has a cash burn of $3 million. While recent financing extends their runway, ongoing losses could pose financial sustainability risks.
Competitive Pressures: The company faces competition in the neuromodulation therapy market, which could impact their ability to secure market share and achieve projected revenues.
Focus Areas for 2024: Helius Medical's focus remains on securing widespread reimbursement for PoNS and achieving FDA approval for stroke.
Financing: Announced $6.4 million financing to extend cash runway into 2025.
Reimbursement Progress: CMS established HCPCS codes for PoNS, enabling negotiations with third-party payers.
Clinical Program Expansion: Added six more sites to the stroke pathway in the U.S. and Canada.
Partnerships: Officially partnered with Global Government Services to make PoNS available to federal healthcare systems.
Canadian Initiatives: Working to establish sites in five regions in Canada as part of a government-funded initiative.
Revenue Expectations: Expect revenues to be muted until reimbursement is established, but anticipate significant revenue boost post-October 1, 2024.
Regulatory Submission Target: Targeting regulatory submission for stroke by early 2025.
Cash Position: As of March 30, 2024, had $3.6 million in cash and no debt.
Future Financing: Potential for additional $6.4 million from warrants if stock price conditions are met.
Public Offering: Closed on a $6.4 million public offering with net proceeds of approximately $5.6 million.
Warrants: Includes one-year warrants for an additional $6.4 million of gross proceeds callable by the company within 30 days of announcing the final reimbursement determination.
Reimbursement Determination: Final determination expected to be announced in late summer, effective October 1, 2024.
The earnings call reveals several concerning factors: a significant unrealized loss on digital assets, high operating expenses, and substantial nonoperating losses. Despite a share buyback program, the financial health appears strained with a large net loss. The market environment is cooling, posing additional risks. No new partnerships or guidance changes were mentioned to counterbalance these negatives. The lack of questions in the Q&A suggests limited analyst engagement or confidence. Overall, these factors point to a likely negative market reaction.
The partnership with Global Government Services is a strong positive, offering access to federal healthcare systems. Financial performance shows improvement, with increased revenue and reduced expenses. The Q&A reveals positive sentiment towards the adoption and geographic expansion of PoNS therapy. However, reimbursement challenges and financial constraints pose risks. Despite these, the optimistic guidance and strategic partnerships suggest a positive stock price movement, likely in the 2% to 8% range over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
